• Explore /
  • Poster
  • / A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma.

A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma.

Abstract Video & Slides Poster

Authors

null

David Bing Zhen

University of Washington/Fred Hutchinson Cancer Center, Seattle, WA;

David Bing Zhen , Ramya Thota , Chris del Corral , Dong Geng , Tairan Yang , Chuan Wang , Gianni Amato , Muhammad Akram , Donna S Miller , Lida Bubuteishvili-Pacaud , Michael K. Gibson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05539430

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS480)

DOI

10.1200/JCO.2023.41.4_suppl.TPS480

Abstract #

TPS480

Poster Bd #

N15

Abstract Disclosures

Similar Posters

First Author: Naval Guastad Daver

First Author: Gregory P. Botta

First Author: Jesus G. Berdeja

First Author: Frederick L. Locke